1/19/2012

Ceptaris' mechlorethamine, a drug candidate for cutaneous T-cell lymphoma, was given orphan-drug status by the European Medicines Agency. The FDA, which previously granted the same designation, is reviewing the gel-based treatment.

Related Summaries